BREAST CANCER

During a live virtual event, Joyce O'Shaughnessy, MD, discussed treatment options for a patient with metastatic triple-negative breast cancer whose disease recurred 8 months after receiving adjuvant therapy.

Alexandra Higgins,MD, discusses the association of hepatopulmonary syndrome with the long-term use of ado-trastuzumab emtansine.

In using the biomarker approach to the treatment of triple-negative breast cancer, the challenge for the clinician is prioritizing the available treatment options based on the National Comprehensive Cancer Network guidelines for breast cancer, which focus on active agents, preferred single-agent chemotherapy approaches, and doublet options for certain patients at high risk.

Two oncologists explain how patients can better understand the NCCN Clinical Practice Guidelines.

Two oncologists discuss the NCCN Clinical Practice Guidelines for triple-negative breast cancer.

Findings from the INSEMA study show that patients who received either sentinel lymph node biopsy or complete axillary lymph node dissection experienced differences in breast and arm symptoms compared with patients who did not.

In the phase 2 I-SPY 2 platform trial, receipt of targeted neoadjuvant chemotherapy did not appear to be based on race.

Adverse events in patients with high-risk HER2-negative early breast cancer treated with chemotherapy before olaparib may be resolved after therapy is complete.

Circulating tumor DNA should be used early and often by physcians who treat patients with early-stage triple-negative breast cancer.

Data from a pooled analysis confirm that patients who self-identify as Black or Hispanic can safely benefit from treatment with palbociclib plus endocrine therapy for hormone receptor–positive, HER2-negative advanced breast cancer.

Compared with tamoxifen, aromatase inhibitors were revealed to be more effective in reducing the rate of recurrence in ER+ breast cancer among premenopausal women receiving ovarian suppression.

Investigators of the SWOG S1007 RxPONDER trial found a statistically significant improvement in invasive disease-free survival and distant relapse-free survival in premenopausal women who received adjuvant chemotherapy.

Data presented at the San Antonio Breast Cancer Sympsium found that in patients with a low HER2 immunohistochemistry (IHC) score of 0 or 1+, poor agreement in the evaluation of these patients exist using standard HER2 assays.

Patients with higher Oncotype DX scores are more likely to complete the recommended 5 years of endocrine therapy.

Phase 3 results from a cohort of patients in China show a progression-free survival benefit with entinostat/exemestane.

Early results from a phase 1 study show promise for datopotamab deruxtecan for patients with advanced or metastatic triple-negative breast cancer.

Results from prespecified subgroup analyses of the phase KEYNOTE-522 study were presented during 2021 SABCS.

Final results from the phase 3 PALLAS study show the addition of palbociclib to endocrine therapy lacks benefit for patients with early hormone receptor-positive, HER2-negative breast cancer.

Updated results from the phase 3 3KEYNOTE-355 trial indicate a new standard of care for patients with metastatic triple-negative breast cancer in patients with a PD-L1 combined positive score of 10 or higher.

Improved invasive disease-free survival or overall survival rates for patients, regardless of hormone receptor status, was not improved with metformin, according to results of a phase 3 trial.

Research shows that tamoxifen treatment may lead to problems down the road in patients with primary breast cancer.

During a press briefing ahead of the 2021 San Antonio Breast Cancer Symposium, results from the phase 3 EMERALD trial were presented.

Imaging mass cytometry at the single-cell level may be a promising response prediction tool for immunotherapy in early triple-negative breast cancer.

In an epidemiological study, a 24-month lymphedema rate of 39.4% was the highest incidence of lymphedema observed among Black women.

A pooled analysis of results from the randomized phase 2 SAFIR02_BREAST and SAFIR-PI3K trials show promise for the use of multigene sequencing to select targeted therapy for metastatic breast cancer.